Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com
by Renee Jackson · The Cerbat GemStockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research note released on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Trading Down 6.2 %
Shares of GLMD stock opened at $4.73 on Tuesday. The business’s fifty day simple moving average is $4.66 and its 200-day simple moving average is $4.35. The company has a market cap of $23.86 million, a PE ratio of -1.97 and a beta of 0.67. Galmed Pharmaceuticals has a 12-month low of $2.73 and a 12-month high of $23.80.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last issued its quarterly earnings results on Wednesday, August 28th. The biopharmaceutical company reported $2.16 earnings per share (EPS) for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Further Reading
- Five stocks we like better than Galmed Pharmaceuticals
- How to invest in marijuana stocks in 7 steps
- When Is the Best Time to Invest in Mutual Funds?
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Is NVIDIA Stock in a Correction or Consolidation?
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- 3 Oversold Stocks with Big RSI Rebound Potential